Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-25-018493
Filing Date
2025-01-31
Accepted
2025-01-31 17:30:52
Documents
6
Effectiveness Date
2025-01-31

Document Format Files

Seq Description Document Type Size
1 S-8 d199531ds8.htm S-8 61609
2 EX-5.1 d199531dex51.htm EX-5.1 10442
3 EX-23.2 d199531dex232.htm EX-23.2 1799
4 EX-FILING FEES d199531dexfilingfees.htm EX-FILING FEES 25382
5 GRAPHIC g199531g14e35.jpg GRAPHIC 2760
6 GRAPHIC g199531g14m14.jpg GRAPHIC 2931
  Complete submission text file 0001193125-25-018493.txt   108432
Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Filer) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-284652 | Film No.: 25579611
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)